Form 4: BioCryst Pharmaceuticals CFO Acquires 36,300 Shares of Common Stock
SEC Form 4 Filing
Anthony Doyle, CFO of BioCryst Pharmaceuticals, recently purchased 36,300 shares of the company's common stock at a price of $5.57 per share.
Summary
- On May 14, 2024, Anthony Doyle, the Chief Financial Officer of BioCryst Pharmaceuticals, acquired 36,300 shares of common stock.
- The purchase price was $5.57 per share.
- Following the transaction, Doyle directly owns 266,744 shares of BioCryst Pharmaceuticals.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. Insider buying can be seen as a positive signal, but it's a single transaction and doesn't provide definitive insight.
Positives
- The CFO's purchase of shares could be interpreted as a sign of confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. Investors often monitor these filings to gain insights into management's perspective on the company's valuation and future performance.
Stakeholder Impact
- Shareholders may view the CFO's stock purchase as a positive signal, potentially increasing investor confidence.
Key Dates
| Date | Description |
|---|---|
| 05/14/2024 | Date of transaction: Anthony Doyle purchased 36,300 shares of BioCryst Pharmaceuticals common stock. |
| 05/15/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.